share_log

微創機器人-B：董事會會議召開日期

MEDBOT-B: DATE OF BOARD MEETING

香港交易所 ·  Mar 15 07:31
Summary by Moomoo AI
上海微創醫療機器人（集團）股份有限公司（「微創機器人-B」）將於2024年3月27日（星期三）召開董事會會議，屆時將考慮及通過包括2023年度業績報告在內的多項議程。會議將討論截至2023年12月31日止的年度業績，並將就是否派發末期股息作出建議。此外，會議還將處理其他事項。董事會由執行董事何超博士、非執行董事孫洪斌先生、陳新星先生、陳琛先生，以及獨立非執行董事李明華博士、姚海嵩先生和梅永康先生組成。
上海微創醫療機器人（集團）股份有限公司（「微創機器人-B」）將於2024年3月27日（星期三）召開董事會會議，屆時將考慮及通過包括2023年度業績報告在內的多項議程。會議將討論截至2023年12月31日止的年度業績，並將就是否派發末期股息作出建議。此外，會議還將處理其他事項。董事會由執行董事何超博士、非執行董事孫洪斌先生、陳新星先生、陳琛先生，以及獨立非執行董事李明華博士、姚海嵩先生和梅永康先生組成。
Shanghai Micro-Chung Medical Robots (Group) Co., Ltd. (“Micro-Chung Robot-B”) will hold a Board Meeting on Wednesday, March 27, 2024, at which time a number of agendas will be considered and adopted, including the 2023 Annual Results Report. The meeting will discuss the annual results for the year ended 31 December 2023 and will make recommendations on whether to issue a final dividend. In addition, the meeting will deal with other matters. The Board of Directors is composed of Executive Director Dr. Ho Chao, Non-Executive Director Mr. Sun Hongbin, Mr. Chen Xinxing, Mr. Chen Achen, and Independent Non-Executive Directors Dr. Lee Ming Wah, Mr. Yao Hai Song and Mr. Mei Yongkang.
Shanghai Micro-Chung Medical Robots (Group) Co., Ltd. (“Micro-Chung Robot-B”) will hold a Board Meeting on Wednesday, March 27, 2024, at which time a number of agendas will be considered and adopted, including the 2023 Annual Results Report. The meeting will discuss the annual results for the year ended 31 December 2023 and will make recommendations on whether to issue a final dividend. In addition, the meeting will deal with other matters. The Board of Directors is composed of Executive Director Dr. Ho Chao, Non-Executive Director Mr. Sun Hongbin, Mr. Chen Xinxing, Mr. Chen Achen, and Independent Non-Executive Directors Dr. Lee Ming Wah, Mr. Yao Hai Song and Mr. Mei Yongkang.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more